The Effect of Preoperative Pelvic Floor Muscle Training on Incontinence Problems after Radical Prostatectomy: A Meta-Analysis

Ervandy Rangganata¹, Harrina Erlianti Rahardjo¹*

Purpose: To evaluate whether additional pelvic floow muscle training (PFMT), which began before radical prostatectomy and resumes immediately after catheter removal, will significantly improve urinary incontinence after RP.

Materials and Methods: We reviewed articles obtained from MEDLINE, CENTRAL, EBSCOHost, CINAHL, and Elsevier from July – August 2020, which compared preoperative PFMT with postoperative PMFT or non-PF-MT, with continence incidence parameters. There were no restrictions on the definition of incontinence, treatment regimens, and radical prostatectomy surgical approach. The risk of bias was assessed using the Cochrane Risk of Bias Assessment Tool. A meta-analysis was also carried out to pool the effect estimates.

Results: We included 12 eligible studies in this review, 11 of which we included in the meta-analysis. The PFMT initiated preoperatively significantly reduced the incidence of persistent urinary incontinence at 1, 3, and 6 months postoperatively with an OR of 0.58 (95% CI, 0.41–0.81), 0.57 (95% CI, 0.43–0.74), and 0.38 (95% CI, 0.17-0.83). There was no difference in improvement in patients' incontinence at 12 months postoperatively [OR = 1.31 (95% CI, 0.65-2.63)].

Conclusion: PFMT initiated before radical prostatectomy significantly reduced the incidence of urinary incontinence in the first, third, and sixth months postoperatively. At 12 months postoperatively, additional preoperative PFMT did not cause a significant difference in urinary incontinence incidence.

Keywords: pelvic floor muscle training; urinary incontinence; radical prostatectomy

INTRODUCTION

Prostate cancer is the second most reported malignancy (after lung cancer) in men worldwide, with 1,276,106 new cases in 2018. Prostate cancer is responsible for 3.8% of all cancer deaths in men in men. 2018. ⁽¹⁾ New cases of prostate cancer are estimated to emerge 2,293,818 cases by 2040, with projections of small variations in mortality in the form of a 1.05% increase.⁽²⁾ About 40% of local prostate cancer patients decided to undergo radical prostatectomy.⁽³⁾

Urinary incontinence is a typical and predictable post-radical prostatectomy episode and is triggered by activities such as sneezing, coughing, lifting, changing positions, and exercising. After prostatectomy, persistent and disturbing urinary incontinence is a commonly reported side effect, with an incidence rate of 1% to 40% postoperatively.⁽⁴⁻⁶⁾ However, this number might be much higher, depending on the definition used and the validity of the incontinence questionnaire used. Post-radical prostatectomy urinary incontinence significantly affects most men's quality of life undergoing surgical management of prostate cancer.⁽⁷⁾ In assessing the quality of life of patients undergoing radical prostatectomy, incontinence was significantly associated with increased confusion, depression, and anger, and inversely related to physical and psychological healthiness.⁽⁸⁾ As many as 28 and 18% of patients in the surgical group from the SPCG-4 study experienced moderate to severe discomfort due to urinary incontinence during the day or night.⁽⁹⁾ Although improvements in surgical techniques have helped reduce the incidence of post-prostatectomy incontinence,⁽¹⁰⁾ the overall rate continues to increase due to an increase in the total number of prostatectomies performed throughout the world.

Several studies recommend delaying invasive urinary incontinence therapy at least one year postoperatively.^(11,12) Therefore, behavioral therapy was chosen in several cases as an alternative.⁽¹³⁾ This noninvasive behavioral therapy consists of diet modification, bladder training, pelvic floor muscle training (PFMT), biofeedback, and functional electrical stimulation. In addition to being inexpensive and practical, they do not involve side effects.⁽¹⁴⁾ However, some randomized controlled trials have investigated pelvic floor muscle training (PFMT) on postoperative urinary incontinence, providing conflicting evidence. While some support PFMT exercise benefits,^(15,16) a Cochrane review in 2015 does not recommend PFM training as a first-line rehabilitation performed post-prostatectomy because there are no significant improvements in UI symptoms over time.⁽¹⁷⁾ The protocol related to PFM training initiated preoperatively and continues postoperatively has not been established yet. The low level of evidence and the lack of systematic reviews that comprehensively review this technique's efficacy might be the contributing factor. On

¹Department of Urology, Cipto Mangunkusumo Hospital—Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia. *Correspondence: Department of Urology, Universitas Indonesia, Jakarta, Indonesia.

Tel: +62 816 825226. E-mail: harrinaerlianti@gmail.com.

Received September 2020 & Accepted April 2021




Figure 1. PRISMA flow chart describes the identification process of included articles.

the other hand, several studies had shown a significant role for PFMT when it is initiated before surgery and/or early postoperatively (< 6 weeks postoperatively).^(18,19) However, some studies also report controversial results. Therefore, the authors would like to evaluate whether a PFMT which begins before radical prostatectomy and resumes immediately after catheter removal, will significantly improve urinary incontinence.

PATIENTS AND METHODS

Description of condition and intervention

This study was compiled based on the preferred reporting items protocol for systematic reviews and meta-analysis (PRISMA) statements. This study attempted to explore the effectivity of PMFT initiated preoperatively in improving urinary incontinence that occurs in patients after radical prostatectomy. Radical prostatectomy techniques were not limited to one particular approach. The use of laparoscopic and robot-assisted technology was also not a criterion for exclusion, as several studies have found there was no significant difference between the type of prostatectomy technique to urinary incontinence.20,21 Improvement of urinary incontinence was not restricted to one definition or parameter. Besides, we also did not limit the types of interventions (PMFT) given to patients, other than the timeline of intervention that must be initiated before radical prostatectomy. A follow-up duration of at least three months was a requirement that must be fulfilled by each study.

Database searching and literature screening

We conducted literature searches using five search engines (Pubmed, Cochrane, EBSCOHost, ProQuest, and Scopus) based on four electronic databases (MEDLINE, CENTRAL, CINAHL, and EMBASE). The search was conducted from July 14 to August 1, 2020. We used PICOS in the literature screening process to assess the suitability of each study for this meta-analysis, as described on supp.Table 1. We used specific keywords, which were tailored to each search engine specification. We also looked at a reference list of several reviews to broaden the scope of study searches.

Study selection

Each author selected the study independently according to inclusion and exclusion criteria. Inclusion criteria in this study included:

1. RCT or quasi-RCT studies comparing PFMT (with or without biofeedback) before and after surgery with PMFT only after radical prostatectomy;

2. English/Indonesian written articles;

3. Full-text articles available;

4. Outcomes are the percentage of patients recovering from incontinence; and

5. Were published in the last 20 years.

We included all types of surgical techniques (open radical prostatectomy, robot-assisted radical prostatectomy, and laparoscopic radical prostatectomy). The definition of incontinence of each study was also not a criterion for study selection. Exclusion criteria of this study included review articles, case reports, case series, editorial letters, studies on animals, and/or studies in the process of peer review (has not been published yet). The determination of study eligibility was determined by each author independently. After that, a full-text analysis was performed on the remaining article. Any disagreement was resolved by discussion.

Data extraction and outcome of interest

Each author conducted data extraction. We extracted the study's primary characteristics, including the first author, location, sample size, year of publication, and




Figure 2. Risk of bias assessment of RCTs using Cochrane Risk of Bias Assessment

patient's demography. We also extracted patient baseline data, including the degree of prostate malignancy and incontinence scores before the intervention (if available). We also extracted patterns or regimens of intervention (PMFT), but there were no restrictions on the pattern of PMFT. Any discrepancies have been resolved by discussion.

This meta-analysis explored the effectiveness of PMFT initiated before radical prostatectomy compared to PFMT initiated following radical prostatectomy or no PFMT at all, in improving the recovery rate of incontinence. The output of this study was the continence rate for each independent variable. We used 2x2 contingency tabs to obtain the ORs for each study and pooled the overall OR using the Review Manager 5 application. Heterogeneity was measured by looking at the I² value. The I2 value greater than 50% indicated a moderate to high heterogeneity. When the high heterogeneity was found between studies, an effect estimate analysis was performed with the DerSimonian and Laird random-effects model. If heterogeneity between studies was low, fixed effect model analysis was performed using the Mantel-Haenszel methods.

Assessment of methodologic quality

This meta-analysis included only RCTs and quasi-RCTs. RCT studies' quality assessment was carried out using the Cochrane risk-of-bias tool for randomized trials (RoB 2). Studies with, at least, moderate quality were included in the overall effect estimate calculation (meta-analysis). Red dot indicated a high risk of bias of each bias criterion, while yellow meant moderate and green meant low risk of bias. Selection bias criterion was not applicable for quasi-RCT study as no random sequence was generated in patient selection. Blinding of participant was also impossible in these settings.

RESULTS

Literature search

A literature search on five electronic databases found 883 articles (first hit), and we found 285 similar articles. For 598 remaining articles, we screened and found that only 17 articles were eligible. We independently conducted a full-text analysis of the remaining 17 articles and found five articles that did not fit the PICOS that we specified in this meta-analysis. We included 12 articles in this review and 11 articles in quantitative synthesis (meta-analysis)—flowchart of this literature search described in **Figure 1**.

Study characteristics

We found 12 eligible studies based on the suitability of patient characteristics, types of interventions in the experimental and control groups, and outcomes measured in each study (**Table 1**). Eleven studies were randomized controlled trials and only 1 study with a quasi-RCT design, which did not implement randomization and patient's data was fully based on the patient's medical record. Five studies lasted for six months, four studies lasted for 12 months, and only three studies lasted for three months. Overall, the total number of patients involved in this study was 1348 patients. 3 of the 12 studies applied the same treatment regimen between the control and experimental groups,⁽²²⁻²⁴⁾ two studies did not apply any treatment to the control group,^(25,26) and the rest applied different treatment regimens. ^(18,19,27–31)

Risk of bias of included studies

Each author assessed each study's quality using the Cochrane Risk of Bias Assessment (RoB) tool for RCT independently. Overall, studies had a high risk of performance bias caused by the impossibility of participants and personnel blinding (**Figure 2**). Therefore, we did not exclude studies just because of the high risk of

	Initiated preoper		Initiated postopera			Odds Ratio	Odds Ratio
study or Subgroup	Events	Total	Events			M-H, Fined, 95% CI	M-H, Fixed, 95% Cl
ales 2000	3.8	47	38	5.0	8.0%	1.33 [0.50, 3.53]	
urgio 2005	5.2	57	54	55	5.5%	0.19 [0.02, 1.70]	
Jentemero 2010	3.3	5.9	47	59	23.5%	0.32 [0.14, 0.73]	
Seraerts 2013	41	85	-41	85	24.1%	1.00 [0.55, 1.83]	
arekh 2003	12	1.9	15	19	6.3%	0.45 [0.11, 1.94]	
ayilan 2018	2.4	30	28	3.0	6.4%	0.29 [0.05, 1.55]	•
Fienforti 2012	10	1.6	16	16	7.2%	0.05 [0.00, 0.96]	
roshida 2018	17	36	51	79	19.1%	0.49 [0.22, 1.09]	
fotal (95% Cl)		349		393	100.0%	0.58 (0.41, 0.81)	•
utal events	227		290				
lenerogeneity: ChP – 1 Fest for overall effect :			- 44%				0.002 0.1 1 10 500 tavoars [Freeperative] tavoars [Postoperative]
B							
-	Initiated preoper		Initiated postopera			Odds Ratio	Odds Ratio
study or Subgroup	Events	Total	Events		Weight P	M-H, Fixed, 95% CI	M-H, Fixed, 95% CI
ales 2000	20	47	19	5.0	7.4%	1.21 [0.54, 2.72]	
urgio 2006	14	57	-4-4	55	12.7%	0.37 [0.16, 0.85]	and the second
Centemero 2010	24	59	37	59	15.4%	0.41 [0.19, 0.85]	
eraerts 2013	18	85	14	85	7.7%	1.36 [0.61, 2.95]	
ira 2019	11	1.5	11	15	2.5%	0.80 [0.17, 3.50]	
arekh 2003		1.9	12	19	5.8%	0.27 [0.07, 1.03]	
atel 2013	41	152	50	132	27.4%	0.61 [0.37, 1.00]	
ayıları 2018	2.3	30	29	3.0	4.7%	0.11 [0.01, 0.99]	
Tenforti 2012	а	1.6	15	16	5.3%	0.07 [0.01, 0.63]	
celticla 201.6	10	36	35	79	11.1%	0.48 [0.71, 1.14]	•
fotal (95% CD							
ocar (55 is civ		517		540	100.0%	0.57 [0.43, 0.74]	•
Fotal events	195 17.17, df = 9 @ -		266 - 48%	540	100.0%	0.57 [0.43, 0.74]	•
Total events Heterogeneity: Chif = 1	17.17, df = 9 (P -	0.05); F -		540	100.0%	0.57 [0.43, 0.74]	0.01 0.1 10 100 favours (Presperative) favours (Postoperative)
Total events Heterogeneity: Chif = 1	17.17, df = 9 (P -	0.05); F -		540	100.0%	0.57 [0.43, 0.74]	b.01 o.1 10 100 favours (Presperative) favours (Postoperative)
Fotal events Belerogeneity: Chi ² = 1 Fest for overall effect :	(7.17, df = 9.0° = Z = 4.12 (P < 0.0	0.05); ř - 001)	- 48%		100.0%	0.57 (0.43, 0.74) Odds Batic	0.01 0.1 10 100 100 100 100 100 100 100
Fotal events Referogeneity: Chi ² = 1 Fest for overall effect :	17.17, df = 9 (P -	0.05); ř - 001)		ively			havours [Preoperative] Havours [Postoperative] Ddds Ratio
For all events Refer against to Chrif = 1 Fest for overall effect : C Red or Subgroup	I Z.17, df - 9 (P - Z = 4.12 (P < 0.0 Initiated preoper Events	0.05); r ² - 001) atively h Total	- 46% nitisted postoperat Events	ively Total	Weight M·	Odds Ratio -H. Rasdom, 95% Cl	Tavours (Presperative) Didds Ratio I M-H, Random, 95% CI
For all events letter againetty: Chif = 1 fest for averall effect : C kudy or Subgroup ales 2000	1×17 , $df = 9 \oplus -$ $Z = 4.12 \oplus < 0.0$ Initiated preoper Events 3	- 0.05); f - 001) atively h	- 4 K%	ively	Weight M- 11.0%	Odds Ratio -H. Rasdom, 95% Cl 1.54 (0.25, 10.26)	Dolds Ratio
forcal events Seterogenetity: Chif = 1 Fest for overall effect : C Study or Subgroup Sales 2006 urglo 2006	I Z.17, df - 9 (P - Z = 4.12 (P < 0.0 Initiated preoper Events	0.05); ř 001) atively h Total 47	- 4105 nitiated postoperat Events 2	ively Total 50	Weight M·	Odds Ratio -H, Raudom, 95% Cl 1.54 (0.26, 10.26) 0.48 (0.73, 1.03)	Didds Ratio
foral events Seterogeneity: Ché – 1 Fest for overall effect : C Study or Subgroup also 2000 argio 2006 events / 2013	17.17, df = 9.09 = Z = 4.12 (P < 0.0 Initiated preoper Events 3 24	otively h Total 42 57	- 4105 nitiated postoperat Events 2 33	ively Total 50 55	Weight M- 11.0% 22.0%	Odds Ratio -H. Rasdom, 95% Cl 1.54 (0.25, 10.26)	Didds Ratio M-H, Random, 95% Cl
Total events teterogenerity: Chif — 1 Test for overall effect : Rudy or Subgroup tales 2000 urglo 2006 eraerts 2013 areach 2003	Initiated preopers Events 3 24	0.050; 1 ² - 0010 Total 42 57 85	- 46% nitiated postoperat Events 2 33 5	ively Total 50 55 85	Weight M- 11.0% 22.0% 15.9%	Odds Ratio -H, Random, 958 Cl 1.64 [0.25, 10.26] 0.48 [0.23, 1.03] 1.00 [0.28, 3.59]	Didds Ratio M-H, Random, 95% Cl
rotal events deterospensity. Chri — – rest for overall effect : study or Subgroup stales 2000 surgio 2006 events, 2013 Parekn 2003 saylan 2018	Initiated preopen Events 2 = 4.12 (P < 0.0 Events 3 24 5 4	0.05); F 001) atively in Total 47 57 85 19	- 4 KS nitiated postoperat Events 33 5 7	Total 50 55 85 19	Weight M- 11.0% 22.0% 15.9% 14.3%	Odds Ratio -H. Random, 958 CI 1.64 [0.26, 10.26] 0.48 [0.28, 1.03] 1.00 [0.48, 3.89] 0.45 [0.11, 1.94]	Didds Ratio
rotal events tetrerogenetity. Chf = - lest for overall effect : kudy or Subgroup lates 2000 undo 2006 enserts 2013 tarekin 2003 explan 2018 lenfort 2012	17.17, df = 9.07 - Z = 4.12 (P < 0.0 Initiated preopen Events 3 24 5 4 15	0.053; F - 001) Total 47 57 85 19 30	- 4 KK nitiated postoperat Events 2 33 5 7 29	total 50 55 85 19 30	Weight M- 11.0% 22.0% 15.9% 14.3% 9.7%	Odds Ratio H. Random, 95% Cl 1.64 [0.25, 10.26] 0.48 [0.23, 1.03] 1.03 [0.48, 3.59] 0.46 [0.11, 1.94] 0.05 [0.00, 0.29]	Didds Ratio
Total events transponters (chr = rest for overall effect) Ready or Subgroup alse 2000 urgb 2006 urgb 2006	Initiated preopers Events 24 24 3 4 3 5 4 5 6	atively h Total 47 57 58 19 16	- 4 KS nitiated postoperat Events 2 3 3 7 7 29 15	Total 50 55 19 10 16 90	Weight M- 11.0% 22.0% 15.9% 14.3% 9.2% 8.4%	Oddw Ratio H. Random, 95N Cl 1.64 (0.25, 10.26) 0.48 (0.23, 1.03) 1.00 (0.48, 3.59) 0.46 (0.11, 1.94) 0.05 (0.00, 0.28) 0.04 (0.00, 0.38)	Didds Ratio M-H, Random, 95% Cl
Total events thereogeneity. Chri — - Test for overall effect : Study or Subgroup stales 2000 Surgio 2006 Generics 2013 Farskin 2003 stylen 2018 Teshida 2015 Teshida 2015	17.17, df = 9.07 - Z = 4.12 (P < 0.0 Events 24 24 3 4 15 6	- 0.05); F - 001) Total 47 57 85 19 30 16 36	- 4 KS nitiated postoperat Events 2 3 3 7 7 29 15	Total 50 55 19 10 16 90	Weight M- 11.0% 22.0% 15.9% 14.3% 9.7% 8.4% 19.3%	Olds Ratio H. Random, 95% Cl 1.44 (0.24, 0.24) 0.46 (0.25, 1.03) 0.46 (0.15, 1.34) 0.46 (0.15, 1.34) 0.34 (0.00, 0.38) 0.40 (0.15, 1.67)	Didds Ratio M-H, Random, 95% Cl
rotal events tetraragenetity. Chri – – Fest for overall effect : Kudy or Subgroup tales 2000 targio 2006 target 2006 target 2008 target 2008 target 2008 target 2008 target 2008 target 2008	17.17, df $10.07 - Z = 4.12$ (P < 0.0 Initial ed preopers Events 3 24 3 24 3 15 15 6 6 0.58: Ch ² = 14.81	• 0.05); F • 001) attively 10 Total 47 57 85 19 16 36 290 9, df = 6 (P	- 48% nitiated postoperat Events 2 33 7 7 7 15 30 1/1	Total 50 55 19 10 16 90	Weight M- 11.0% 22.0% 15.9% 14.3% 9.7% 8.4% 19.3%	Olds Ratio H. Random, 95% Cl 1.44 (0.24, 0.24) 0.46 (0.25, 1.03) 0.46 (0.15, 1.34) 0.46 (0.15, 1.34) 0.34 (0.00, 0.38) 0.40 (0.15, 1.67)	Didds Ratio N-H, Random, 95% Cl
Total events tetrarogenetics Chri – Test for svera il effect : C C Uddy or Subgroup lates 2000 urgbs 2006 events //113 arcsh 2003 argin 2015 enfota 2015 reach 2012 reach 2012 reach 2012 reach 2012 reach 2012 reach 2012 reach 2015 reach 2015 r	$ \begin{array}{l} 17.17, \ df & 0.0^{-} \\ Z = 4.12 \ (P < 0.0 \\ \hline \\ \text{Events} \\ 3 \\ 24 \\ 5 \\ 4 \\ 15 \\ 6 \\ 6 \\ 0.58; \ Ch^2 = 13.8; \\ Z = 2.43 \ (P = 0.02 \\ \hline \end{array} $	- 0.05(; f ² - 001) Total 47 57 85 36 36 290 3, df = 5 (P	- 48% nitialed postoperat Events 2 3 7 7 15 30 1/1 - 0.03); I' = 57%	Total 50 55 83 19 10 15 345	Weight M- 11.06 15.95 15.95 8.45 8.45 19.35 19.35	Cidds Ratio H. Random, 958 Cl 1.64 (0.25, 10.26) 0.48 (0.23, 1.03) 1.00 (0.48, 3.59) 0.46 (0.11, 1.94) 0.54 (1.05, 0.28) 0.40 (0.0, 0.38) 0.40 (0.15, 1.07) 0.38 (0.17, 0.83)	Didds Ratio N-H, Random, 95% Cl
Total events terrespondy C (b) = - Test for overall effect (Rudy or Subgroup alse 2000 urgo 2006 urgo 2006 verseris 2013 arskn 2003 verseris 2013 arskn 2003 verseris 2015 testal (2005 testal (2005) testal (2005) tes	17.17 , $df = 0.0^{-}$ Z = 4.12 ($P < 0.00Initial of preoper-Events24341560.58; Ch^2 = 13.85Z = 2.43$ ($P = 0.62Initial of preop$	- 0.055; f ² - 001) Total 47 57 85 10 13 13 10 13 13 10 13 36 290 3, df = 6 (P 2) peratively	- 48% initiated postoperat Events 2 3 7 79 15 30 	Total 50 55 19 10 10 10 10 10 345	Weight M: 11.05 22.05 15.95 0.95 0.95 19.35 19.35 100.05	Odds Ratio H. Random, 958 CI 1.54 (0.24, 10.26) 0.48 [0.73, 1.03] 0.40 [0.48, 3.59] 0.46 [0.10, 1.194] 0.46 [0.10, 0.38] 0.46 [0.10, 1.07] 0.40 [0.15, 1.67] 0.43 [0.17, 0.83]	Didds Ratio M-H, Random, 55% Cl M-H, Random, 55% Cl Didds Ratio 0.01 Favours [Preoperative] Didds Ratio 0.01 Favours [Preoperative] Odds Ratio
Total events terresponders (chr - Test for overall effect : C C C C C C C C C C C C C	$ \begin{array}{l} z_{+} z_{+} d^{-1} = 0, p - \\ z_{-} = 4, 12 \ (P < 0, 0) \\ \hline \\ \text{Initiated preopen} \\ \frac{3}{24} \\ \frac{3}{4} \\ \frac{3}{$	• 0.05; f - 001) • Total 4/ 57 85 16 290 3, df = 5 (P Peratively Tota	- 48% nitialed postoperat Events 2 3 7 7 7 15 30 7 7 15 30 7 7 15 30 7 7 15 30 7 15 30 7 15 30 7 15 30 15 15 15 15 15 15 15 15 15 15	Total 50 55 19 10 10 10 10 10 345	Weight M 11.05 22.05 14.35 8.45 100.05 100.05 100.05 100.05 100.05	Odds Ratio H. Random, 958 Cl 1.64 (0.25, 10.26) 0.48 (0.23, 1.03) 1.00 (0.28, 3.59) 0.46 (0.11, 1.94) 0.54 (1.05, 0.28) 0.40 (0.0, 0.38) 0.40 (0.15, 1.07) 0.38 (0.17, 0.83) Odds Ratio th M-H, Fixed, 955	Didds Ratio N-H, Random, 95% CI 0.01 0.1 10 10 0005 Ratio 0.01 L0 10 10 0005 Ratio 0.01 L0 10 10 0005 Ratio 0.01 L0 10 CI M-H, Fixed, 95% CI
Total events tetraragenetis, Chrif – – Fest for overall effect : C Study or Subgroup states 2000 surgels 2006 surgels 2006 surgels 2008 surgels 200	$ \begin{array}{c} 17, 17, 41 & 0.0 \\ \mathbf{z} = 4, 12 \ (P < 0.0 \\ \textbf{ballint ad preopers} \\ \textbf{Events} \\ 3 \\ 24 \\ 5 \\ 4 \\ 15 \\ 6 \\ \textbf{6} \\ \end{array} \\ \begin{array}{c} 0.58; Ch^2 = 13.85 \\ \textbf{7} = 2.43 \ (P = 0.02 \\ \textbf{ballint ad preop} \\ \textbf{Events} \\ \textbf{20} \end{array} $	0.035; f ² - 001) Total 47 57 57 57 57 57 57 57 57 57 57 57 57 59 0 3, df = 5 (P 2) perati vely 55	- 48% nitiated postoperat Events 2 33 7 79 15 30 7 2 - 0.02); I' = 57% Initiated postop I Events 5 9	Total 50 55 19 10 10 10 10 10 345	Weight M: 11.355 12.355 14.355 0.755 8.455 19.355 100.095	Odda Ratio H. Random, 95N CJ 1.64 (0.24, 0.24) 0.49 [0.73, 1.03] 0.00 [0.13, 1.04] 0.01 [0.13, 1.04] 0.40 [0.15, 1.07] 0.40 [0.15, 1.07] 0.43 [0.17, 0.33] Odds Ratio t: M -H, Fined, 955	Didds Ratio M-H, Random, 55% Cl 5.01 0.1 Havours [Preoperative] Havours [Postoperative] CC Odds Ratio M-H, Fired, 95% Cl
Total events there-generally. Chif = - Fest for overall effect : Rest for overall effect : Rest for overall effect : Rest overall effect : Rest 2000 servers 2018 forekt 2003 servers 2018 forekt 2015 forekt 2015	$ \begin{array}{l} z_{-1}z_{+} d^{-1} = 0, p = \\ z = 4.12 \ (P < 0.0) \\ \hline \\ \mbox{ Initiated preopen} \\ z = 2.4 \\ 0 \\ z = 2.4 \\ 0 \\ 0.58; \ Ch^2 = 14.8i \\ 0.58; \ Ch^2 =$	- 0.035; f ² - 001) Total 4 57 57 58 19 10 15 15 16 15 290 8, df = 5 (P 2) Tota 55 8 8 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10	- 48% nitiated postoperat Events 2 3 7 7 7 15 30 7 7 15 30 7 7 15 30 7 7 15 30 7 15 30 7 15 30 7 15 30 7 15 30 15 30 7 7 15 30 15 30 7 7 15 30 15 15 30 15 15 15 15 15 15 15 15 15 15	Total 50 55 83 19 16 90 345 345	Weight M 11.06 22.06 14.36 0.75 8.46 19.35 10000 19.35 10000 Y Y Y Y Y S 28.16 45 42.7 85 28.16 19.35 10.3	Cidds Ratio - H. Random, 958 Cl 1.64 (0.25, 10.26) 0.48 (0.23, 1.03) 1.00 (0.28, 3.59) 0.46 (10.11, 1.94) 0.54 (1.00, 0.28) 0.40 (0.0, 0.38) 0.40 (0.0, 0.38) 0.40 (0.0, 0.38) 0.40 (0.17, 0.43) 0.58 (0.17, 0.43) Cidds Ratio t M-H, Fixed, 958 5 0.49 (0.49, 2.1)	Didds Ratio N-H, Random, 95% Cl 0.01 August Preoperative] L0 10 0.01 August Preoperative] Favours (Prestoperative) 10 Cl M-H, Fixed, 95% Cl 2.6] M-H, Fixed, 95% Cl 2.6] M-H, Fixed, 95% Cl
Total events thereagenety Christ Test for overall effect : C C C C C C C C C C C C C	$ \begin{array}{c} 17, 17, 41 & 0.0 \\ \mathbf{z} = 4, 12 \ (P < 0.0 \\ \textbf{ballint ad preopers} \\ \textbf{Events} \\ 3 \\ 24 \\ 5 \\ 4 \\ 15 \\ 6 \\ \textbf{6} \\ \end{array} \\ \begin{array}{c} 0.58; Ch^2 = 13.85 \\ \textbf{7} = 2.43 \ (P = 0.02 \\ \textbf{ballint ad preop} \\ \textbf{Events} \\ \textbf{20} \end{array} $	- 0.035; f - 0011) Total 47 57 16 36 290 3, df = 5 (P) peratively Tota 5; 11 12 12 12 12 12 12 12 12 12	- 48% - 48% - 48% - 48% - 48% - 48% - 58% - 57% -	Total 50 55 19 16 9 345 345	Weight M. 11.05 72.05 15.95	Odds Ratio -H, Random, 958 Cl 1.44 (0.25, 10.26) 0.48 (0.25, 10.33) 0.04 (0.25, 1.03) 0.40 (0.15, 1.07) 0.38 (0.17, 0.83) Odd Ratio t H-H, Fined, 958 5 0.49 (0.03, 2 0.40 (0.15, 1.07) 0.38 (0.17, 0.83) Cdds Ratio	Didds Ratio M-H, Random, 95% CI 0.01 0.1 Favours [Preoperative] Favours [Fostoperative] 0.01 0.1 Favours [Preoperative] Favours [Fostoperative] 0 dds Ratio 0 dds Ratio 0 dds Ratio 0 dds Ratio
Total events territrogonnity Chif — Test for overall effect : C C C C C C C C C C C C C	$ \begin{array}{l} z_{-1}z_{+} d^{-1} = 0, p = \\ z = 4.12 \ (P < 0.0) \\ \hline \\ \mbox{ Initiated preopen} \\ z = 2.4 \\ 0 \\ z = 2.4 \\ 0 \\ 0.58; \ Ch^2 = 14.8i \\ 0.58; \ Ch^2 =$	- 0.035; f ² - 001) Total 4 57 57 58 19 10 15 15 16 15 290 8, df = 5 (P 2) Tota 55 8 8 8 8 10 10 10 10 10 10 10 10 10 10 10 10 10	- 48% - 48% - 48% - 48% - 48% - 48% - 58% - 57% -	Total 50 55 19 16 9 345 345	Weight M 11.06 22.06 14.36 0.05 8.46 19.35 10000 19.35 10000 Y Y Y Y Y S 28.16 45 42.7 8 5 2 2 10 10 10 10 10 10 10 10 10 10	Odds Ratio -H, Random, 958 Cl 1.44 (0.25, 10.26) 0.48 (0.25, 10.33) 0.04 (0.25, 1.03) 0.40 (0.15, 1.07) 0.38 (0.17, 0.83) Odd Ratio t H-H, Fined, 958 5 0.49 (0.03, 2 0.40 (0.15, 1.07) 0.38 (0.17, 0.83) Cdds Ratio	Didds Ratio M-H, Random, 95% CI 0.01 0.1 Favours [Preoperative] Favours [Fostoperative] 0.01 0.1 Favours [Preoperative] Favours [Fostoperative] 00dds Ratio 0.01 10 68]

Figure 3. Forest plot shows odds ratio of getting incontinence after radical prostatectomy at several time points: (A) 1 month; (B) 3 months; (C) 6 months; and (D) 12 months.

performance bias. In general, the studies included in this meta-analysis were of good quality. The selection bias from the study of Patel et al. 2013 could not be assessed because this study was a quasi-RCT study. We found a large variety of interventions given to patients in each study, which was generally based on each health center's protocol, where the study was conducted. PFMT accompanied and guided by a physiotherapist, followed by a biofeedback session, was the most widely

Intervention regimen




Figure 4. Funnel plot shows the distribution of studies based on the effect estimate and standard error: (A) 1 month; (B) 3 months; (C) 6 months; and (D) 12 months.

Author	Intervention*	Timing	Control†	Ν	Age (yr)	Duration
Bales et al. 2000.27	Nurse guided graded PFMT with biofeedback	4 times/day 2–4 weeks to surgery	Oral and verbal advice to perform PFMT without biofeedback	47/50	59.3/60.9	6 months
Burgio et al. 2006.19	Instruction of PFMT with single session of biofeedback	NR	Verbal advice to perform PFMT	57/55	$\begin{array}{c} 60.7 \pm 6.6 \\ 60.7 \pm 6.6 \end{array}$	6 months
Centemero et al. 2010.18	Physiotherapist guided PFMT with visual feedback	Twice per week (30 minutes), 2–4 weeks preoperatively	Verbal instruction of PFMT with visual feedback	59/59	60.5 (48–68) 57.5 (46–67)	3 months
Collado et al. 2013.28	Written instruction of PFMT with weekly assisted-biofeedback session and TVA	3 weeks preoperatively	Verbal instruction of Kegel exercise	87/92	NR	12 months
Dijkstra-Eshuis et al. 2015.22	Physiotherapist guided PFMT with biofeedback and ES	30 minutes weekly,4 weeks preoperatively	Physiotherapist guided PFMT with biofeedback and ES	65/56	63.7 ± 5.3	12 months
Geraerts et al. 2013.23	Guided PFMT with digital/EMG biofeedback	30 minutes weekly, 3 weeks preoperatively	Guided PFMT with digital/EMG biofeedback	85/85	61.88 (44–73 62.04 (41–76	
Lira et al. 2019.25	Physiotherapist guided PFMT with EMG biofeedback	3 times/day 3 weeks preoperatively	Postoperative care without PFMT	16/15	$\begin{array}{c} 63.53 \pm 7.62 \\ 67.3 \pm 5.63 \end{array}$	3 months
Parekh et al. 2003.29	Formal instruction with 2 sessions of guided PFMT	2 sessions preoperatively	Non-formal PFMT instruction	19/19	55.5/61.6	12 months
Patel et al. 2013.24	Physiotherapist guided PFMT with visual feedback	1–4 sessions (1 hour), 4 weeks preoperatively	Physiotherapist guided PFMT with visual	152/132	60 (41–76)/ 62 (44–76)	3 months
Sayilan et al. 2018.26	5 Guided PFMT with visual feedback	1–4 sessions (1 hour), 1 week preoperatively	feedback No exercise instruction	30/30	$\begin{array}{c} 63.00 \pm 8.61 \\ 59.93 \pm 6.98 \end{array}$	6 months
Tienforti et al. 2012.30	Supervised PFMT with biofeedback	1 day preoperatively	Oral and written instructions of PFMT	16/16	67 (60–74)/ 64 (52–74)	6 months
Yoshida et al. 2018.31	Physician guided PMFT with single session US-biofeedback	1 month preoperatively	Verbal instruction of PFMT	36/80	$\begin{array}{c} 66.5 \pm 6.2 / \\ 66.5 \pm 5.8 \end{array}$	6 months

Table 1. Characteristic of the study included in this systematic review.

* Interventions were given both before and after surgery; † Interventions were given postoperatively only; NR: not reported; TVA: transversus abdominis activation; ES: electrical stimulation; PFMT: pelvic floor muscle training; EMG: electromyographic; US: ultrasound

used treatment regimen.^(18,22,24,25) Only the Parekh et al. (2003) study did not include biofeedback in the treatment regimen.⁽²⁹⁾ Most studies conducted training and biofeedback sessions at least once a week for 30–60 minutes per session, four weeks before radical prostatectomy. Only the Tienforti et al.⁽³⁰⁾ and Sayilan et al.⁽²⁶⁾ studies conducted therapy less than two weeks before radical prostatectomy, and two studies did not report the specific time of the PFMT therapy initiation.^(19,29)

Incontinence rate at several time points

We compiled incontinence rates between studies in the form of OR patients experience post-radical prostatectomy incontinence at several time points (**Table 2 and Figure 3**). In the first 1-month after radical prostatectomy, we found that the experimental group had a significantly lower risk for incontinence after radical prostatectomy. The significance of this risk difference is was marked by the low OR and the width of the confidence interval that does did not exceed one unit [OR = 0.58 (95% CI, 0.41-0.81)]. The heterogeneity between studies was also not significant (I² = 44%, *p* = 0.09), so we performed calculations using the Mantel-Haenszel fixed-effect model.

At three months postoperatively, the incontinence rate's

difference between the experimental and control groups also remained significant. The experimental group's odds ratio for incontinence compared to the control group at three months postoperatively was 0.57 (95% CI, 0.43–0.74), with no significant heterogeneity between studies (I² = 48%, p = 0.05). Only two studies reported that the control group reported a lower risk of persistent incontinence than the experimental group. ^(23,27)

Six months postoperatively, the incidence of urinary incontinence was still significantly lower in the experimental group. At this time point, the experimental group's odds ratio to the control group was 0.38 (95% CI, 0.17–0.83), with significant heterogeneity between studies ($I^2 = 57\%$, p = 0.03). Only seven studies compared incontinence in the experimental and control groups in the 6th-month post radical prostatectomy, and only two studies reported a significantly higher incidence of persistent urinary incontinence six months postoperatively in the control group. The minimum number of studies involved in the meta-analysis for this six-month time point and the considerable variation in odds ratios between studies might become the cause of high heterogeneity between studies.

There were only three studies comparing incontinence

Author	n	Continence definition	Types of prostatectomy	1 mo	Incontine 3 mo	ence (OR) 6 mo	12 mo	Quality
Bales et al. 2000	47/50	The use of ≤ 1 pad per day	NR	1.33	1.21	1.64	NR	Fair
Burgio et al. 2006	57/55	No leakage (3 consecutive weekly 1-day diaries/7- day diary)	NR	0.19	0,37	0.48	NR	Fair
Centemero et al. 2010) 59/59	No urinary leakage in bladder diary and a negative stress test	ORP	0.32	0.41	NR	NR	Fair
Collado et al. 2013	87/92	Not reported	NR	NR	NR	NR	NR	Fair
Dijkstra-Eshuis et al. 2015	65/56	No leakage at all on a 24-hr pad test, PeLFIs, and KHQ	LARP	NR	NR	NR	2.11	Fair
Geraerts et al. 2013	85/85	3 days of 0 g of urine loss on the 24-h pad test	RARP and ORP	1.00	1.36	1.00	0.49	Fair
Lira et al. 2019	16/15	Patient's perception of loss of at least a few drops of urine	ORP	NR	0.80	NR	NR	Good
Parekh et al. 2003	19/19	The use of ≤ 1 pad per day	NR	0.46	0.27	NR	0.79	Fair
Patel et al. 2013	152/132	Patient-reported one pad	ORP	NR	0.61	NR	NR	Poor
Sayilan et al. 2018	30/30	usage/day ICIQ-UI score of zero	NR	0.29	0.11	0.03	NR	Good
Tienforti et al. 2012	16/16	ICIQ-UI score of zero	ORP	0.05	0.07	0.04	NR	Good
Yoshida et al. 2018	36/80	The number of days requiring a small pad (20 g	NR)/day	0.49	0.48	0.40	NR	Good

NR: not reported, ORP: open radical prostatectomy, RARP: robot-assisted laparoscopic radical prostatectomy, LARP: laparoscopic radical prostatectomy

events at 12 months post radical prostatectomy.(22,23,29) None of these studies reported significant differences between incontinence events in the experimental and control groups. Therefore, we also found something similar in the meta-analysis at that time point. We found no significant difference between the control and experimental groups on experiencing incontinence 12-month after radical prostatectomy, with the experimental group's tendency to be more susceptible [OR = 1.31 (95% CI, 0.65-2.63), $I^2 = 30\%$, p = 0.44]

We used a funnel plot to predict the probability of publication bias in this meta-analysis (Figure 4). The risk of publication bias was relatively high in several outcomes: six months and 12 months after surgery. The low number of studies assessing these outcomes, especially 12 months postoperatively, variations in patient characteristics and outcome measurement, and the inclusion of studies with low quality were thought to cause the high risk of publication bias.

Subgroup analysis was not carried out as we did not find any relevant characteristic that might influence the outcome. The types of prostatectomy (ORP, LARP, RARP) did not significantly affect the incontinence rate after prostatectomy.(20,21)

DISCUSSION

Persistent and disturbing urinary incontinence after prostatectomy is a commonly reported side effect postoperatively, with an incidence rate of 1% to 40%.(4-6) Several studies recommend delaying invasive urinary incontinence therapy at least one year postoperatively.

Review 385

(11,12) Therefore, behavioral therapy was chosen in some cases as an alternative.⁽¹³⁾ This noninvasive behavioral therapy consists of diet modification, bladder training, pelvic floor muscle training (PFMT), biofeedback, and functional electrical stimulation. Apart from being cheap and practical, these therapies have never been reported to cause any side effects.⁽¹⁴⁾

Urinary continence depends on the smooth and striated muscle fibers' complex interactions that work sinergically to form a continuity mechanism. Some authors are still debating about whether incontinence after prostatectomy is due to effects on the detrusor muscle (bladder) or the sphincter. Detrusor overactivity and intrinsic sphincter insufficiency due to sphincteric injury are the most important causes of persistent incontinence after radical prostatectomy. Some reports mention that detrusor overactivity is a significant cause of postprostatec-tomy incontinence,^(32,33) others strongly argue that even if other factors play a role, intrinsic sphincter deficiency is the main cause of UI after radical prostatectomy.⁽³⁴⁻³⁶⁾ Detrusor overactivity is an incontinence pathophysiology that is corrected by PFMT. This method includes exercising specific pelvic floor voluntary muscle contractions using biofeedback, as well as coordinating and determining the time of contraction for increased intraabdominal pressure. Specific and repetitive contractions of the pelvic floor muscles can increase strength and efficiency when there is an increase in intraabdominal pressure; thus, this would suppress detrusor overactivity. Berghmans and colleagues reported that pelvic floor muscle contractions effectively held the urethra by

providing structural support to the pelvic organs; and PFMT triggers hypertrophy of the urethral muscular muscles thereby increasing mechanical pressure on the urethra, which in turn can prevent detrusor overactivity and prevent urinary incontinence.⁽³⁷⁾

Several clinical studies have proven that the strength of PFM correlates with incontinence and that PFMT increases the strength of PFM can effectively speed up the recovery of incontinence in patients post radical prostatectomy.^(17,38) In this study, we found that PFMT carried out before radical prostatectomy significantly reduced the risk of persistent urinary incontinence one month after radical prostatectomy OR = 0.58 (95%) CI, 0.41–0.81)], compared to patients who underwent PFMT only after surgery or did not undergo PFMT at all. This reduction in incontinence risk is consistent for up to 6 months postoperatively, in which most studies agree that the experimental group has a much higher rate of continence than the control group. At 12 months postoperatively, the control group could achieve the same continence rate as the experimental group, indicating that almost all patients in both groups had regained continence at 12 months postoperatively [OR = 1.31 (95% CI, 0.65–2.63)].

This meta-analysis combined several radical prostatectomy approaches, such as open radical prostatectomy (ORP), laparoscopic radical prostatectomy (LARP), and robot-assisted (RARP). A combination of these approaches was undertaken to increase the heterogeneity of studies extrapolated in various clinical settings. Moreover, several prospective comparative studies found no statistically significant difference in urinary incontinence between post-ORP, LRP, or RARP patients.^(20,21)

Our findings are in line with Chang et al. (2016), who included six studies in their meta-analysis to determine the effect of PFMT in improving incontinence. The study found that the experimental group's odds were lower in 1, 3, and 6 months postoperatively and were significantly different in the three months postoperatively.⁽³⁹⁾ Some previous meta-analyses reported the opposite of what we found. Wang et al. (2014) reported no significant difference in the incidence of the relative risk of persistent incontinence at 1, 3, 6, and 12 months post radical prostatectomy.⁽⁴⁰⁾ However, this study included no more than four studies for meta-analysis, and there were only two studies that have good quality. A meta-analysis by Wu et al. (2019) found that guided-PF-MT effectively reduced the risk of persistent incontinence at all time points, and preoperative guide-PFMT did not provide any benefit to patients. However, this study only included two studies and two-time points (3 and 6 months), and had a high heterogeneity (79%). The impact of incontinence on a patient's quality of life is clearly visible. Geraerts et al. (2013) reported a smaller reduction in quality of life in the preoperative exercise group, and all patients in the experimental group expressed satisfaction in receiving PFMT before surgery.⁽²³⁾ Research by Centemero et al. (2010) showed that 75% of patients in the intervention group reported a high level of satisfaction by starting PFMT before surgery.⁽¹⁸⁾ Considering that urinary incontinence is a complication that significantly reduces the quality of life, any intervention that can shorten its duration is worth a try. Moreover, patients who receive additional PFMT before surgery show a high level of satisfaction, so

PMFT can be a noninvasive therapy option that should be recommended to patients before radical prostatectomy.

There are several limitations in this meta-analysis that may interfere with the interpretation of final results. We found considerable heterogeneity between studies. This heterogeneity arises due to the large variety of PFMT regimens in each study. For example, PFMT accompanied and guided by a physiotherapist, accompanied by a biofeedback session, is the most widely used treatment regimen, but only 4 of 12 studies used this treatment regimen. One included study did not even include biofeedback in the treatment regimen. The definition of the "intervention group" in each study also varies. Three studies considered the intervention as an additional PFMT so that the treatment regimen between the control and experimental groups was the same, with the only difference being the time the therapy was started. Moreover, the definition of incontinence and continence of each study was also diverse, and it was impossible to establish a single definition of incontinence as an inclusion criterion. Some other things that cause high heterogeneity were surgery techniques, the frequency of PFMT intervention, and the time of initiation of preoperative and postoperative PFMT. Our meta-analysis included quite a large number of studies, and most had a low risk of bias, considering that participant blinding was not possible in this study with PICO.

CONCLUSIONS

PFMT initiated before radical prostatectomy significantly reduced the incidence of urinary incontinence in the first, third, and sixth months postoperatively. At 12 months postoperatively, additional preoperative PFMT did not cause a significant difference in the incidence of urinary incontinence.

CONFLICT OF INTEREST

The authors report no conflict of interest.

ACKNOWLEDGMENTS

The first author of the paper (E. Rangganata) received a scholarship from Indonesia Endowment Fund for Education (LPDP scholarship) from the Ministry of Finance, Republic of Indonesia.

REFERENCES

- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394– 424.
- 2. Rawla P. Epidemiology of Prostate Cancer. World J Oncol. 2019;10:63–89.
- **3.** Cooperberg MR, Broering JM, Litwin MS, Lubeck DP, Mehta SS, Henning JM, et al. The contemporary management of prostate cancer in the United States: lessons from the cancer of the prostate strategic urologic research endeavor (CapSURE), a national disease registry. J Urol. 2004;171:1393–401.
- **4.** Krupski TL, Saigal CS, Litwin MS. Variation in continence and potency by definition. J Urol. 2003;170:1291–4.

- Olsson LE, Salomon L, Nadu A, Hoznek A, Cicco A, Saint F, et al. Prospective patientreported continence after laparoscopic radical prostatectomy. Urology. 2001;58:570–2.
- Rodriguez E, Skarecky DW, Ahlering TE. Post-robotic prostatectomy urinary continence: characterization of perfect continence versus occasional dribbling in pad-free men. Urology. 2006;67:785–8.
- Talcott JA, Rieker P, Propert KJ, Clark JA, Kantoff PW, Wishnow KI, et al. Patient-Reported Impotence and Incontinence After Nerve-Sparing Radical Prostatectomy. J Natl Cancer Inst. 1997;89:1117–23.
- 8. Braslis K g., Santa-Cruz C, Brickman A l., Soloway M s. Quality of life 12 months after radical prostatectomy. British Journal of Urology. 1995;75:48–53.
- 9. Johansson E, Steineck G, Holmberg L, Johansson J-E, Nyberg T, Ruutu M, et al. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial. The Lancet Oncology. 2011;12:891–9.
- **10.** Hu JĆ, Elkin EP, Pasta DJ, Lubeck DP, Kattan MW, Carroll PR, et al. Predicting quality of life after radical prostatectomy: results from CaPSURE. J Urol. 2004;171:703–7; discussion 707-708.
- 11. Ficarra V, Borghesi M, Suardi N, De Naeyer G, Novara G, Schatteman P, et al. Long-term evaluation of survival, continence and potency (SCP) outcomes after robot-assisted radical prostatectomy (RARP). BJU Int. 2013;112:338–45.
- **12.** Frawley HC, Dean SG, Slade SC, Hay-Smith EJC. Is Pelvic-Floor Muscle Training a Physical Therapy or a Behavioral Therapy? A Call to Name and Report the Physical, Cognitive, and Behavioral Elements. Phys Ther. 2017;97:425–37.
- **13.** Meyer P. [Algorithms and urinary incontinence in the elderly. Assessment, treatment, recommendations and levels of evidence. Review]. Prog Urol. 2017;27:111–45.
- Santa Mina D, Matthew AG, Hilton WJ, Au D, Awasthi R, Alibhai SMH, et al. Prehabilitation for men undergoing radical prostatectomy: a multi-centre, pilot randomized controlled trial. BMC Surg. 2014;14:89.
- **15.** Prota C, Gomes CM, Ribeiro LHS, de Bessa J, Nakano E, Dall'Oglio M, et al. Early postoperative pelvic-floor biofeedback improves erectile function in men undergoing radical prostatectomy: a prospective, randomized, controlled trial. Int J Impot Res. 2012;24:174–8.
- **16.** Filocamo MT, Li Marzi V, Del Popolo G, Cecconi F, Marzocco M, Tosto A, et al. Effectiveness of early pelvic floor rehabilitation treatment for post-prostatectomy incontinence. Eur Urol. 2005;48:734–8.
- Anderson CA, Omar MI, Campbell SE, Hunter KF, Cody JD, Glazener CMA. Conservative management for postprostatectomy urinary

incontinence. Cochrane Database Syst Rev. 2015;1:CD001843.

- Centemero A, Rigatti L, Giraudo D, Lazzeri M, Lughezzani G, Zugna D, et al. Preoperative Pelvic Floor Muscle Exercise for Early Continence After Radical Prostatectomy: A Randomised Controlled Study. European urology. 2010;57:1039–43.
- **19.** Burgio KL, Goode PS, Urban DA, Umlauf MG, Locher JL, Bueschen A, et al. Preoperative biofeedback assisted behavioral training to decrease post-prostatectomy incontinence: a randomized, controlled trial. J Urol. 2006;175:196–201; discussion 201.
- Haglind E, Carlsson S, Stranne J, Wallerstedt A, Wilderäng U, Thorsteinsdottir T, et al. Urinary Incontinence and Erectile Dysfunction After Robotic Versus Open Radical Prostatectomy: A Prospective, Controlled, Nonrandomised Trial. European Urology. 2015;68:216–25.
- **21.** Jacobsen N-EB, Moore KN, Estey E, Voaklander D. Open Versus Laparoscopic Radical Prostatectomy: A Prospective Comparison of Postoperative Urinary Incontinence Rates. The Journal of Urology. 2007;177:615–9.
- **22.** Dijkstra-Eshuis J, Van den Bos TWL, Splinter R, Bevers RFM, Zonneveld WCG, Putter H, et al. Effect of preoperative pelvic floor muscle therapy with biofeedback versus standard care on stress urinary incontinence and quality of life in men undergoing laparoscopic radical prostatectomy: a randomised control trial. Neurourol Urodyn. 2015;34:144–50.
- 23. Geraerts I, Van Poppel H, Devoogdt N, Joniau S, Van Cleynenbreugel B, De Groef A, et al. Influence of preoperative and postoperative pelvic floor muscle training (PFMT) compared with postoperative PFMT on urinary incontinence after radical prostatectomy: a randomized controlled trial. Eur Urol. 2013;64:766–72.
- 24. Patel MI, Yao J, Hirschhorn AD, Mungovan SF. Preoperative pelvic floor physiotherapy improves continence after radical retropubic prostatectomy. Int J Urol. 2013;20:986–92.
- 25. Lira GHS de, Fornari A, Cardoso LF, Aranchipe M, Kretiska C, Rhoden EL, et al. Effects of perioperative pelvic floor muscle training on early recovery of urinary continence and erectile function in men undergoing radical prostatectomy: a randomized clinical trial. International braz j urol. 2019;45:1196–203.
- Aydın Sayılan A, Özbaş A. The Effect of Pelvic Floor Muscle Training On Incontinence Problems After Radical Prostatectomy. Am J Mens Health. 2018;12:1007–15.
- **27.** Bales GT, Gerber GS, Minor TX, Mhoon DA, McFarland JM, Kim HL, et al. Effect of preoperative biofeedback/pelvic floor training on continence in men undergoing radical prostatectomy. Urology. 2000;56:627–30.
- 28. Collado SA, Pellicer CM, Ramirez BM, Dominguez-Escrig J, Rubio-Briones J, Gomez-Ferrer A, et al. 1007 Intensive preoperatory Pelvic Floor Muscle Training

reduce duration and severity of stress urinary incontinence after radical prostatectomy: A randomized controlled trial. European Urology Supplements. 2013;12:e1007–8.

- **29.** Parekh AR, Feng MI, Kirages D, Bremner H, Kaswick J, Aboseif S. The role of pelvic floor exercises on post-prostatectomy incontinence. J Urol. 2003;170:130–3.
- **30.** Tienforti D, Sacco E, Marangi F, D'Addessi A, Racioppi M, Gulino G, et al. Efficacy of an assisted low-intensity programme of perioperative pelvic floor muscle training in improving the recovery of continence after radical prostatectomy: a randomized controlled trial. BJU Int. 2012;110:1004–10.
- **31.** Yoshida M, Matsunaga A, Igawa Y, Fujimura T, Shinoda Y, Aizawa N, et al. May perioperative ultrasound-guided pelvic floor muscle training promote early recovery of urinary continence after robot-assisted radical prostatectomy? Neurourol Urodyn. 2019;38:158–64.
- **32.** Leach GE. Post-prostatectomy incontinence: the importance of bladder dysfunction. J Urol. 1995;153:1038.
- Goluboff ET, Saidi JA, Mazer S, Bagiella E, Heitjan DF, Benson MC, et al. Urinary continence after radical prostatectomy: the Columbia experience. J Urol. 1998;159:1276– 80.
- **34.** Aboseif SR, O'Connell HE, Usui A, McGuire EJ. Collagen injection for intrinsic sphincteric deficiency in men. J Urol. 1996;155:10–3.
- Chao R, Mayo ME. Incontinence after radical prostatectomy: detrusor or sphincter causes. J Urol. 1995;154:16–8.
- 36. Majoros A, Bach D, Keszthelyi A, Hamvas A, Romics I. Urinary incontinence and voiding dysfunction after radical retropubic prostatectomy (prospective urodynamic study). Neurourol Urodyn. 2006;25:2–7.
- **37.** Berghmans LC, Hendriks HJ, Bo K, Hay-Smith EJ, de Bie RA, van Waalwijk van Doorn ES. Conservative treatment of stress urinary incontinence in women: a systematic review of randomized clinical trials. Br J Urol. 1998;82:181–91.
- **38.** Manley L, Gibson L, Papa N, Beharry BK, Johnson L, Lawrentschuk N, et al. Evaluation of pelvic floor muscle strength before and after robotic-assisted radical prostatectomy and early outcomes on urinary continence. J Robot Surg. 2016;10:331–5.
- **39.** Chang JI, Lam V, Patel MI. Preoperative Pelvic Floor Muscle Exercise and Postprostatectomy Incontinence: A Systematic Review and Metaanalysis. Eur Urol. 2016;69:460–7.
- **40.** Wang W, Huang QM, Liu FP, Mao QQ. Effectiveness of preoperative pelvic floor muscle training for urinary incontinence after radical prostatectomy: a meta-analysis. BMC Urol [Internet]. 2014 [cited 2020 Aug 4];14. Available from: https://www.ncbi.nlm.nih. gov/pmc/articles/PMC4274700/
- **41.** Wu M-L-Y, Wang C-S, Xiao Q, Peng C-H, Zeng T-Y. The therapeutic effect of pelvic

floor muscle exercise on urinary incontinence after radical prostatectomy: a meta-analysis. Asian J Androl. 2019;21:170–6.